SCHEMBL6824951

SCHEMBL6824951

Oc1cccc(-c2ccc[c]c2O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 11/20 0.48
HSD17B2 P37059 10/20 0.48
CYP3A4 P08684 3/20 0.48
CYP2C9 P11712 2/20 0.48
ESR1 P03372 2/20 0.41
ESR2 Q92731 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2B6 P20813 1/20 0.41
CYP2C19 P33261 1/20 0.41
CA12 O43570 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CA2 P00918 1/20 0.41
LMNA P02545 1/20 0.41
CA5A P35218 1/20 0.41
CA9 Q16790 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CA14 Q9ULX7 1/20 0.41
CA5B Q9Y2D0 1/20 0.41
PIK3CD O00329 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21647115 0.81 BIRC5 (0.36) CYP1A2ALDH1A1LMNA
SCHEMBL21647114 0.81 ALOX5 (0.46) ESR2CA12CA9SRCCDK9
SCHEMBL4288525 0.81 HSD17B1 (0.45) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL4275992 0.81 HSD17B1 (0.50) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL4283341 0.81 HSD17B1 (0.45) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL4285032 0.81 HSD17B1 (0.45) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL1921664 0.81 HSD17B1 (0.45) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL1501857 0.79 ALDH1A1 (0.50) ESR2ALDH1A1HSD17B10
SCHEMBL8102071 0.78 ABL1 (0.47) HSD17B1HSD17B2ESR1ESR2ALDH1A1
SCHEMBL4279339 0.78 HSD17B1 (0.41) HSD17B1HSD17B2CYP3A4CYP2C9ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6737409-B2 FOR CANCER THERAPY HOFFMANN-LA ROCHE INC. 2004-05-18 US disclosed
US-20030055002-A1 Dolastatin 10 derivatives HOFFMANN-LA ROCHE INC. 2003-03-20 US disclosed
EP-0730601-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTIONS WASHINGTON UNIVERSITY (US) 1996-09-11 EP disclosed
EP-0524419-B1 Heat-sensitive recording materials and phenol compounds MITSUI TOATSU CHEMICALS (JP) 1995-09-06 EP disclosed
WO-1995014028-A2 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTIONS WASHINGTON UNIVERSITY (US) 1995-05-26 WO disclosed
US-5391806-A A storage stable chromogens as color-developing agent or stabilizers MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1995-02-21 US disclosed
US-5270281-A Chromogenic compound MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1993-12-14 US disclosed
EP-0524419-A1 Heat-sensitive recording materials and phenol compounds MITSUI TOATSU CHEMICALS, Inc. (JP) 1993-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055002-A1 Dolastatin 10 derivatives DAD1, DDOST, NPC1 HSD17B1 697/4885HSD17B2 1483/4885CYP3A4 1278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.